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Background: Colonoscopy is one of the most effective methods of cancer prevention and detection, particularly
for individuals with familial risk. Recruitment of family members to behavioral intervention trials remains uniquely
challenging, owing to the intensive process required to identify and contact them. Recruiting at-risk family
members involves contacting the original cancer cases and asking them to provide information about their at-risk
relatives, who must then be contacted for study enrollment. Though this recruitment strategy is common in family
trials, few studies have compared influences of patient and relative participation to nonparticipation. Furthermore,
although use of cancer registries to identify initial cases has increased, to our knowledge no study has examined
the relationship between registries and family recruitment outcomes.
Methods: This study assessed predictors of case participation and relative enrollment in a recruitment process that
utilized state cancer registries. Participation characteristics were analyzed with separate multivariable logistic
regressions in three stages: (1) cancer registry-contacted colorectal cancer (CRC) cases who agreed to study contact;
(2) study-contacted CRC cases who provided at-risk relative information; and (3) at-risk relatives contacted for
intervention participation.
Results: Cancer registry source was predictive of participation for both CRC cases and relatives, though relative
associations (odds ratios) varied across registries. Cases were less likely to participate if they were Hispanic or
nonwhite, and were more likely to participate if they were female or younger than 50 at cancer diagnosis. At-risk
relatives were more likely to participate if they were from Utah, if another family member was also participating in
the study, or if they had previously had a colonoscopy. The number of eligible cases who had to be contacted to
enroll one eligible relative varied widely by registry, from 7 to 81.
Conclusions: Family recruitment utilizing cancer registry-identified cancer cases is feasible, but highly dependent
on both the strategies and protocols of those who are recruiting and on participant characteristics such as sex,
race, or geography. Devising comprehensive recruitment protocols that specifically target those less likely to enroll
may help future research meet recruitment goals.
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Colorectal cancer (CRC) is the second leading cause of
cancer mortality in the United States, yet the risk of
contracting this lethal disease can vary significantly, owing
to genetic factors [1]. A family history of CRC in close rel-
atives increases the lifetime risk of developing the disease
by two-to-eight fold [2,3]. Risk varies with the age of onset
of CRC in family members, as well as with the number
and type of relatives (first-, second-, and third-degree) [4].
Colonoscopy is the recommended screening test for these
individuals; however, adherence to screening recommen-
dations is disappointingly low (<50% in most studies)
[5-7]. Research on methods to improve colonoscopy
screening within this population is crucial to improving
the health of at-risk families, yet has been hampered, be-
cause of the challenges of recruiting adequate numbers of
study participants.
Recruitment of family members to cancer screening
behavioral intervention trials poses several unique chal-
lenges to researchers. Family history of CRC is not well
documented in medical records, which means that re-
searchers must often obtain at-risk relative information
by first identifying original cancer cases [8]. These cancer
cases are contacted and asked to provide information
about potentially at-risk relatives who must then be
contacted, screened, and recruited for study participation.
At each stage of the process, barriers can affect participa-
tion and impair recruitment, which inflates overall study
costs and timetables [9,10].
Recruitment Stage 1: case identification
Cancer registries, particularly state-based cancer regis-
tries, represent an ideal source for population-based case
identification. However, registries may differ significantly
in their research recruitment protocols, which may affect
overall recruitment accrual [11]. To date, no research has
examined how differences in registry research recruitment
polices might affect recruitment of CRC patients. Our
study examined initial characteristics of different state
registry recruitment protocols and followed registry source
as a potential participation and recruitment factor through-
out each stage of the recruitment process.
Recruitment Stages 2 and 3: case participation and
relative enrollment
Identifying demographic and medical factors affecting case
participation and relative recruitment provides important
information to those seeking to optimize participation infuture research, yet few studies have reported such factors
in cases or relatives recruited to familial cancer behavioral
intervention trials. To our knowledge, only three studies
have provided predictors of recruitment to familial cancer
behavioral intervention trials. A recent melanoma preven-
tion study [12] predicted family participation for relatives
who were female, younger at cancer diagnosis, married,
and living nearer to the cancer case. Another study, aimed
at improving colonoscopy screening, [13] found no predic-
tors of participation in cancer cases who provided at-risk
relative contact information. To our knowledge, there is
only one published cancer screening behavioral interven-
tion trial that reports factors affecting participation of both
cases and siblings [14]. In this study, both male cancer
cases and relatives were less likely to participate. The clin-
ical characteristics of cases, including cancer stage, year of
diagnosis, and age at diagnosis were assessed but none of
these factors was found to significantly influence enroll-
ment [15]. Our study is among the first to report on par-
ticipation and recruitment characteristics of both cases and
different types of relative, such as parents, children, and
second-degree relatives. Current clinical guidelines suggest
earlier colonoscopy screening for individuals who have two
or more second-degree relatives with CRC; thus, examin-
ing factors related to enrollment in these individuals is an
important aspect of a family intervention trial [6].
This study seeks to build upon previous research of
predictors of family-based enrollment in behavioral inter-
vention trials designed to motivate cancer screening. To
our knowledge, this is the first multisite family-based CRC
study that uses population-based recruitment strategies
with multiple state cancer registries to examine baseline
demographic and clinical predictors of recruitment of
both cancer cases and their first- and second-degree at-
risk relatives. Our study is also the first of its kind to
report the direct costs associated with family recruitment.
Recruitment outcomes of our study may provide useful in-
formation to investigators interested in reaching these
difficult-to-access populations.Methods
Family CARE project overview
The Family Colorectal Cancer Awareness and Risk Edu-
cation Project (Family CARE) is a randomized, con-
trolled trial investigating whether a personalized, remote,
theoretically-based risk-assessment and telephone coun-
seling intervention is more effective than a mailed, low-
intensity targeted print message delivered to individuals
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CRC. At-risk family members who enrolled in the study
were randomized by family unit to either the tailored
intervention group or the minimal intervention group. A
detailed description of the study intervention theory and
methods is provided elsewhere [15]. A total of 481 first-
and second-degree relatives were enrolled in the study
between September 2009 and September 2011. Ethical
approval for all study procedures and recruitment proto-
cols were approved by the Institutional Review Boards of
participating institutions, which are listed as follows:
University of Utah Institutional Review Board; Utah Can-
cer Registry Advisory Research Committee Resource for
Genetic and Epidemiologic Research; Committee for the
Protection of Human Subjects through the California Pub-
lic Health Institute; Idaho Cancer Analysis Work Group;
University of New Mexico Human Research Review Com-
mittee Institutional Review Board; Colorado Department
of Public Health and Environment Institutional Review
Board; Intermountain Healthcare Institutional Review
Board; Cancer Genetics Network Steering Committee; and
University of Colorado Multi-Insitutional Review Board
(protocol #10-0243).
Participants
Individuals were enrolled in the Family CARE study
through a three-stage recruitment process. Eligibility
was determined at each stage of recruitment. A CON-
SORT diagram of the study recruitment process up to
enrollment and randomization of relatives is provided in
Additional file 1.
Recruitment Stage 1: registry case contact
The majority (97.1%) of participants in our study were
recruited from five state cancer registries: California,
Colorado, Idaho, New Mexico, and Utah. A small num-
ber of cases (2.9%) were drawn from Cancer Genetics
Network (CGN) registries and hospital-based registries
[16]. Registries differed from one another with regard to:





California Cancer Registry 2005 to 2008 None
Cancer Data Registry of
Idaho
1971 to 2007 Passive
Colorado Cancer Registry 2003 to 2009 Passive
New Mexico Tumor Registry 2000 to 2009 Passive
Utah Cancer Registry 1971 to 2008 None
aPassive physician notification provides physicians a time-based opt-out period in w
degree relative (FDR) of an individual diagnosed with colorectal cancer (CRC) betwe
CRC at any age AND one additional FDR or second-degree relative with a relative d
cHigh: both phone and mail follow-up. Moderate: at least one mail follow-up. Low:required prior to contacting cases; (2) opt-out and opt-
in participation policies; (3) consent process (written,
telephone, or passive consent); (4) intensity level of the
cases contact and follow-up (defined in Table 1); and (5)
cases diagnosis years included in each registry’s sampling
frame. Table 1 outlines state-registry-specific protocols.
CRC cases were eligible to refer their relatives for par-
ticipation if they met particular criteria for age, cancer
site (ICD-O codes: C18.0 to C20.9, excluding 18.1), hist-
ology (8140–8143, 8190, 8210, 8211, 8260–8263, 8480,
8481, 8490, 8510), and year of diagnosis, which varied by
registry (Table 1). The Utah Cancer Registry and the
Cancer Data Registry of Idaho differed from other par-
ticipating registries in that they received a preselected
list of cases that met the family risk criteria for the study
from the Utah Population Database, a unique genea-
logical database containing records for multiple genera-
tions of families [17]. This database also allowed study
investigators to identify eligible first- and second-degree
relatives for possible inclusion in the study.
Once registries had obtained cases consent, informa-
tion about cancer cases was passed on to Family CARE
study staff to begin Stage 2 of the recruitment process.Recruitment Stage 2: cancer case contact by Family CARE
staff
To obtain information about potentially eligible relatives,
Family CARE staff contacted all registry-identified cases.
Cases were mailed an introductory letter, study bro-
chure, and family contact form (FCF), which requested
the contact information of potentially eligible relatives.
Cancer cases who did not return the FCF received
follow-up calls from Family CARE staff seven days after
study packet mailings. As suggested by Durrant et al.
[18], follow-up calls were made within four time slots
(morning, afternoon, evening, weekend) to ensure the
highest probability of contact. Staff sent nonresponders
a noncontact form, which included options to provide







Passive Group 1 Low
Written only Group 1, Group 2 High
Written only Group 1 Moderate
Written only Group 1 Low
Phone or written Group 1, Group 2 High
hich physicians can refuse patient contact for a study.bGroup 1: one first-
en 40 and 60 years of age. Group 2: one FDR with a relative diagnosed with
iagnosed with CRC at any age (CRC cases must be related to one another).
no follow-up.
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and contact.
Cases who provided information about their relatives
were sent a thank-you letter; and their relatives’ informa-
tion was grouped by a family identification number, in
preparation for Stage 3.
Recruitment Stage 3: relative contact by Family CARE staff
Relatives were mailed a consent document, a study bro-
chure, and an initial letter informing them that Family
CARE staff would be telephoning them to determine
their eligibility and interest in participating, and to an-
swer questions about the study. Relatives were eligible to
participate in the study if they had a first-degree relative di-
agnosed with CRC between the ages of 40 and 49 (partici-
pant age, 30 to 74), if they had a first-degree relative
diagnosed with CRC between the ages of 50 and 59 (par-
ticipant age, 40 to 74), or if they had a first-degree relative
diagnosed with CRC at age 60 or over, plus an additional
first- or second-degree relative diagnosed with CRC at any
age (participant age, 40 to 74). Relatives were ineligible for
participation if they had a previous cancer diagnosis (other
than nonmelanoma skin cancer or a pediatric cancer) or a
colonoscopy within the last five years; if they were currently
participating in any other research study; if they could not
read, write, and speak English, or were mentally incompe-
tent or currently incarcerated; if they had a relative with a
molecular or clinical diagnosis of Lynch syndrome or an-
other hereditary cancer syndrome; or if they had received
previous clinical or research-based cancer-risk counseling
or evaluation or had previously participated in a clinical
trial or a behavioral or epidemiologic familial cancer study.
Relatives who were screened and determined to be in-
eligible received a personalized thank-you letter with in-
formation on CRC screening and prevention. If, during
the screening process, an ineligible relative disclosed a
family history that appeared to indicate a genetic condi-
tion (such as Lynch syndrome), the Family CARE staff
would make a referral for genetic counseling at a local
cancer genetics clinic [19]. Eligible relatives completed a
baseline questionnaire by mail, phone, or the Internet.
Once baseline questionnaires were completed, relatives
were enrolled in the study and randomized to one of the
two study arms. Individuals with other participating family
members were enrolled into the same study arm, to reduce
the risk of cross-contamination.
Measures
Response rate measures
Response rates (RR) for registries and FCF returns were
calculated using the RR1 formula for mailed surveys to spe-
cifically named persons formulated by the American Asso-
ciation for Public Opinion Research (AAPOR) [20].The
RR1 is calculated as the number of complete interviews (I)divided by the number of complete and partial interviews
(P) plus the number of noninterviews (refusals (R), non-
contacts (NC), others (O)) plus all cases of unknown eligi-
bility (unknown if household occupied (UH), other
unknown(UO)):
RR1 ¼ I= Iþ Pð Þ þ RþNCþOð Þ þ UHþ UOð Þ
For relative enrollment, RRs were calculated using the
RR3 formula for mailed surveys to specifically named
persons, which accounts for the proportion of individ-
uals with unknown eligibility who actually may have
been eligible (e):
RR3 ¼ I= Iþ Pð Þ þ RþNCþOð Þ þ e UHþ UOð Þ
Cost measures
We examined direct recruitment costs for cases and rel-
atives at each of the three stages of recruitment. Direct
costs included direct staff time and labor for telephone
contact, direct staff time and labor to compile and mail
all letters and questionnaires, and costs of printing, mail-
ing materials, and postage.
Study variable measures
Demographic information for cancer cases (including
cancer stage, sex, age, diagnosis age, race, ethnicity, and
census tract-level rural or urban residence) was obtained
from state cancer registries. Cases provided information
on their at-risk relatives including name, age, address, and
sex. ZIP codes were used to determine rural or urban sta-
tus, according to codes established by the United States
Department of Agriculture [21]. The relative screening
survey included questions about race, ethnicity, personal,
and family history of CRC, CRC screening history, and
age. Many cases did not provide accurate information
about their relatives’ ages, so cross-checking was required
to maintain data accuracy.
Statistical analysis
We generated descriptive statistics to characterize cases
and relatives at respective recruitment stages. We then
conducted bivariate analysis, calculating crude odds ratios
(OR) and 95% confidence intervals (CI), to determine fac-
tors associated with participation at each recruitment
stage. Differences were tested using Wald chi-square tests.
Multivariable logistic regression analyses were performed
to generate ORs and 95% CIs of factors that showed asso-
ciation. Fully adjusted models were run to estimate predic-
tors at each stage of study recruitment. Owing to
differences in registry recruitment protocols at Stage 1,
inter-registry statistical comparisons were not possible.
We excluded California from this analysis level because
the passive consent recruitment process resulted in only
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small for predictive analyses. Thus, intra-registry associa-
tions for Colorado, Idaho, New Mexico, and Utah are
presented. All analyses were conducted using SAS 9.2
(SAS Institute Inc., Cary, NC, 2008).
Results
Response response rates
A total of 8,318 individuals were contacted through the
five state registries (Table 2). The registry with the
highest RR was the California registry (86.9%), which
utilized an opt-out protocol wherein individuals uninter-
ested in study contact were required to call the registry
to opt out of future contact. The lowest RR was the New
Mexico registry (7.7%), which required written consent
for future study contact and informed participants about
the study through a single mailed information packet.
Family contact form response rates
A total of 4,139 FCFs were sent; later, 256 of those who
received FCFs were determined to be ineligible. Only
2,043 of the FCFs were returned, giving a return rate of
52.6% (Table 2). Of the FCFs returned, 726 cases listed
an average of three (range: 1 to 26 on a single form) po-
tentially eligible relatives for contact.
Relative enrollment response rate’s
A total of 2,435 potentially eligible relatives were contacted
for the study, with 1,394 determined ineligible during that
process (Table 2). There were 364 individuals whose eligi-
bility status was unknown, either through noncontact or
because they declined initial participation, whom we had
initially categorized as eligible. Using the AAPOR RR3Table 2 Family CARE Study response rates for the three-stage
relatives, 2009 to 2011.
Total selected Ineligib




New Mexico 1,029 3
Utah 2,543 329
Other registry sourcesa N/A N/A
Stage 2 Family contact form responseb 4,139c 256
Stage 3 At-risk relative study enrollment 2,435 1,394
aOf the other nonstate registry sources utilized in the Family CARE study, only Inter
contacted cases to obtain consent for Family CARE study contact. Other nonstate re
Applications Core (TRAC)) provided case information directly to Family CARE study
nature of case ascertainment and consent, it is not possible to identify which of the
not included.bFor the Family Contact Form (FCF), ‘consented’ means that the case r
consent’ means that the case either did not return the FCF form or refused to parti
rather than by participating registries, are included in this number.dThis number ref
file 2).eResponse rates for at-risk relatives were calculated using the AAPOR RR3 form
relatives known to be eligible.formula, we calculated the proportion of these individuals
likely to be actually eligible as 32.7%, for a total number of
119. Of those estimated to be study eligible (n = 628), 481
individuals were randomized into one of the two study
arms, resulting in a RR of 60.4%.
Cost per participant outcomes
A cost breakdown by recruitment stage by state cancer
registry is provided in Table 3. Costs to recruit one state
registry case at Stage 1 varied widely, from $5.69 to
$28.69 (average cost, $18.15); this spread was largely de-
termined by the intensity of case follow-up. State regis-
tries that did not require physician notification, used a
single mailing contact, or did not perform follow-up
calls (New Mexico and California) had lower registry re-
cruitment costs. Moderate costs occurred in state regis-
tries that had a large number of cases and followed
moderate-or high-intensity contact regimens. The cost
of recruiting at-risk relatives to the study (Stage 3) was
slightly higher ($6.14 more) than the cost of contacting
CRC cases (Stage 2). These results do not include costs
incurred for the 2.9% of cases provided from nonstate
registry sites.
Predictors of registry consent outcomes
Predictors of participation differed by registry. Adjusted
ORs and 95% CIs are presented by state registry in
Table 4 (crude ORs by state are presented in Additional
file 2). Cases in Utah were less likely to participate if
they were older (≥50) when diagnosed with CRC (OR:
0.74, 95% CI: 0.55, 0.98). Nonwhite race was associated
with nonparticipation in both Colorado (OR: 0.39, 95%
CI: 0.19, 0.76) and Utah registries (OR: 0.21, 95% CI:recruitment process of cancer cases and their at-risk
le Eligible Consented Did not consent Response rate
2,753 2,391 362 86.9%
983 335 648 34.1%
601 137 464 22.8%
1,026 79 947 7.7%
2,214 1,004 1,210 45.3%
245 61 184 24.9%
3,883 2,043 1,840 52.6%
1,041d 481 560 60.4%e
mountain Healthcare and the New Mexico Cancer Genetics Network (CGN)
gistries (Utah CGN, Huntsman Cancer Registry, and Tissue Resource and
staff in accordance with individual registry protocols. Owing to the diverse
initially selected cases were counted as ineligible. Thus, these numbers are
eturned the FCF, with or without names of eligible relatives, while ‘did not
cipate. cIndividuals who were contacted directly by Family CARE staff (n = 132)
ers to response rate eligibility (differentiated from study eligibility in Additional
ula: The basis for our estimates was calculated from the response rate of
Table 3 Cost per participant at each of the three stages









New Mexico $5.69 Low
Utah $23.02 High








aCosts per stage only account for direct costs involved in the recruiting
process, including direct staff time and labor for telephone contact, direct staff
time and labor to compile and mail all letters and questionnaires, and material
costs associated with printing, mailing materials, and postage.bHigh: both
phone and mail follow-up. Moderate: at least one mail follow-up or one phone
follow-up. Low: no follow-up.
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in Utah (OR: 0.39, 95% CI: 0.24, 0.61).Predictors of FCF return outcomes
Table 5 shows the crude and adjusted ORs for variables
associated with FCF return by cases. Both Hispanic eth-
nicity (OR: 0.62, 95% CI: 0.50, 0.78) and nonwhite race
(OR: 0.66, 95% CI: 0.51, 0.84) were negatively associated
with FCF return. Rural residents were more likely to re-
turn the FCF than those in urban settings (OR: 1.31,
95% CI: 1.08, 1.58). Sex was also significantly associated
with FCF return, as women were more likely than men
to participate (OR: 1.25, 95% CI: 1.07, 1.46). The stron-
gest association was registry source; individuals recruited
from Idaho (OR: 8.28, 95% CI: 5.11, 13.41), Colorado
(OR: 7.12, 95% CI: 5.97, 18.98), New Mexico (OR: 3.32,
95% CI: 2.04, 5.41), and Utah (OR: 10.89, 95% CI: 8.08,
14.66) were more likely to participate than individuals
recruited from California.Predictors of relative enrollment outcomes
Table 6 presents the crude and adjusted odds ratios for
the association between potential predictive factors and
relative enrollment status in the study. Individuals with
other family members participating in the study were
more likely to enroll than those without family participa-
tion (OR: 1.57, 95% CI: 1.06, 2.70). Individuals from
Utah were more likely to participate than those recruited
from other states (OR: 1.74, 95% CI: 1.17, 2.60). Individ-
uals who had previously undergone a colonoscopy were
more likely to enroll than those who had never had a
colonoscopy (OR: 1.69, 95% CI: 1.05, 2.70).Total study participation outcomes
The number of eligible cases who were contacted in
order to enroll one eligible relative in the study varied
markedly by registry. The largest difference was in the
California registry; 81 cases were contacted to enroll one
relative. The smallest difference was through the Utah
registry, where seven cases were required to enroll one
relative. Ratios for all state registries, including Idaho
(14:1), Colorado (32:1), and New Mexico (68:1) exhibited
inverse dose response levels congruent with the amount
of contact intensity that each registry allowed for the ini-
tial case contact.
Discussion
Recruiting at-risk relatives to this behavioral randomized
controlled trial was logistically challenging, with large
numbers of cancer cases required to enroll one eligible
relative. High contact intensity registries (Utah and
Idaho) required fewer cases to recruit one eligible rela-
tive, whereas the medium contact intensity registry
(Colorado) required moderate numbers of cases to enroll
one relative and the lowest contact intensity registries
(New Mexico and California) required the most cases to
recruit one relative.
Although California initially yielded the largest num-
ber of cases with the lowest level of effort, individuals
contacted through this registry were less likely to partici-
pate than individuals contacted using other registries. It
is noteworthy that the California registry was the only
participating registry that utilized passive consent for
study contact, whereby individuals were informed of
study contact via a single mailing with no follow-up; and
case names were forwarded to Family CARE staff unless
they notified the registry that they wished to decline
study contact. Other state registries with higher contact
intensity (phone follow-up, phone or mail consent re-
quired, additional mailings) were found to yield higher
participation rates. In other words, the more contact in-
tensity, the more likely cases were to participate. A
qualitative study of participant recruitment for familial
cancer research by Kreiger et al. [22] found that cancer
cases approached for familial research expressed con-
cerns about providing information about at-risk relatives
for research purposes. It is possible that more intensive
cancer registry contact and information about the study
alleviated some concerns that cases felt, particularly in
registries that performed phone follow-up and could an-
swer specific questions about the study.
Subsequently, both Stages 2 and 3 of the recruitment
process required intensive contact measures, including
notification calls, mailings, postcards, reminder calls,
and second or third mailings. Despite recruitment inten-
sity, initial registry source continued to be predictive of
case participation and relative enrollment in our study.























Consent/nonconsent 335/648 137/464 79/947 1,004/1,210
Case age group at contact
≤49 Referent Referent Referent Referent N/A N/A Referent Referent
50 to –59 1.29 0.76, 2.18 1.13 0.52, 2.47 1.25 0.87, 1.81
≥60 1.19 0.65, 2.25 0.69 0.27, 1.78 1.14 0.75, 1.75
Case age group at diagnosis
≤49 Referent Referent Referent Referent Referent Referent Referent Referent
≥50 0.84 0.57, 1.23 1.84 0.98, 3.46 0.88 0.51, 1.52 0.74 0.55, 0.98
Diagnosis yeard
Before 2000 Referent Referent Referent Referent
2000 to 2004 Referent Referent 2.03 0.79, 5.23 Referent Referent 1.01 0.81, 1.27
2005 to 2009 0.84 0.57, 1.22 1.71 0.66, 4.41 1.63 0.97, 2.74 1.07 0.85, 1.36
Cancer stage
Local Referent Referent Referent Referent Referent Referent Referent Referent
Regional 1.06 0.80, 1.41 1.00 0.67, 1.49 1.44 0.89, 2.32 1.18 0.97, 1.42
Distant 1.15 0.69, 1.91 0.87 0.67, 1.13
Sex
Female 1.19 0.91, 1.57 1.08 0.73, 1.61 1.23 0.76, 1.99 0.89 0.76, 1.06
Male Referent Referent Referent Referent Referent Referent Referent Referent
Race
Nonwhite 0.39 0.19, 0.76 0.68 0.14, 3.19 N/A N/A 0.21 0.08, 0.56
White Referent Referent Referent Referent Referent Referent
Ethnicity
Hispanic 0.89 0.60, 1.32 N/A N/A 0.83 0.50, 1.37 0.39 0.24, 0.61
Non-Hispanic Referent Referent Referent Referent Referent Referent
Rural or urban status
Rural 0.94 0.63, 1.40 1.18 0.78, 1.78 N/A N/A 1.06 0.83, 1.36
Urban Referent Referent Referent Referent Referent Referent
aAdjusted odds ratio is defined as the full regression model, with all variables included in the analyses. Full individual registry analyses including total numbers and crude odds ratios can be found in Additional file 2.
Owingto their passive consent process, California was not included in the analysis as numbers of nonconsenting cases (n = 26) were too small to examine.bAll consenting cases provided by the Idaho registry were of
non-Hispanic ethnicity. Thus, ethnicity was excluded from Idaho analyses.cOwing to HIPAA privacy concerns, New Mexico did not provide age, race, or rural or urban status of nonconsenting individuals. Thus, these






























Total number 2,043 (52.6%) 1,840 (47.4%)
Case age group at study
contact
≤49 199 (47.8%) 217 (52.2%) Referent Referent Referent Referent
50 to 59 920 (47.4%) 1019 (52.6%) 0.98 0.79, 1.22 1.02 0.76, 1.36
60+ 924 (60.5%) 604 (39.5%) 1.67 1.34, 2.08 1.16 0.82, 1.65
Case age group at
diagnosis
≤40 60 (69%) 27 (31%) Referent Referent Referent Referent
41 to 50 600 (49.3%) 618 (50.7%) 0.44 0.27, 0.69 0.82 0.45, 1.48
51+ 1,383 (53.6%) 1,195 (46.4%) 0.52 0.33, 0.83 0.84 0.45, 1.57
Diagnosis year
Before 2000 194 (84%) 37 (16%) Referent Referent Referent Referent
2001 to 2004 406 (85.3%) 70 (14.7%) 1.11 0.72, 1.71 1.30 0.83, 2.05
2005 to 2009 1,443 (45.4%) 1,733 (54.6%) 0.16 0.11, 0.23 1.27 0.80, 2.00
Ethnicitya
Hispanic 163 (31.2%) 360 (68.8%) 0.39 0.32, 0.47 0.62 0.50, 0.78
Non-Hispanic 1,656 (54%) 1,410 (46%) Referent Referent Referent Referent
Race
Nonwhite 329 (48.9%) 344 (51.1%) 0.84 0.71, 0.98 0.66 0.51, 0.84
White 1,714 (53.4%) 1,496 (46.6%) Referent Referent Referent Referent
Rural or urban status
Rural 425 (57.2%) 318 (42.8%) 1.26 1.07, 1.48 1.31 1.08, 1.58
Urban 1,618 (51.5%) 1,522 (48.5%) Referent Referent Referent Referent
Sex
Female 960 (55.6%) 767 (44.4%) 1.24 1.09, 1.41 1.25 1.07, 1.46
Male 1,083 (50.2%) 1,073 (49.8%) Referent Referent Referent Referent
Cancer stage
Local 869 (49%) 905 (51%) Referent Referent Referent Referent
Regional or distant 1,174 (55.7%) 935 (44.3%) 1.31 1.15, 1.48 1.05 0.91, 1.23
Registry source
California 827 (33.9%) 1,611 (66.1%) Referent Referent Referent Referent
Idaho 115 (83.9%) 22 (16.1%) 10.18 6.40, 16.19 8.28 5.11, 13.41
Colorado 213 (81.9%) 47 (18.1%) 8.83 6.37, 12.24 7.12 5.97, 18.98
New Mexico 51 (64.6%) 28 (35.4%) 3.55 2.22, 5.67 3.32 2.04, 5.41
Utah 837 (86.4%) 132 (13.6%) 12.35 10.09, 15.11 10.89 8.08, 14.66
aNot all cases had available ethnicity data.
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http://www.trialsjournal.com/content/14/1/116Kreiger et al. [22] found that individuals were more will-
ing to participate in research if the study were endorsed
by a trusted and familiar source. Our results indicate that
cases recruited from Utah and Idaho were most likely to
return the FCF and that at-risk relatives were more likely
to participate if they were Utah residents; this may be re-
sult from participants’ familiarity with and recognition of
Huntsman Cancer Institute at the University of Utah, the
study coordinating site. These findings emphasize thepotential impact of participant familiarity with research
groups on study participation.
Cancer registry recruitment costs were lower in state
registries that utilized low-intensity contact procedures.
However, the cases provided by these registries required
more intensive and costly recruitment efforts by study
staff, and ultimately yielded fewer total eligible relatives
than registries with higher contact intensity. For example,
the California registry yielded high numbers of potential













Total number 2,043 (52.6%) 1,840 (47.4%)
Case age group at study
contact
≤49 199 (47.8%) 217 (52.2%) Referent Referent Referent Referent
50 to 59 920 (47.4%) 1019 (52.6%) 0.98 0.79, 1.22 1.02 0.76, 1.36
60+ 924 (60.5%) 604 (39.5%) 1.67 1.34, 2.08 1.16 0.82, 1.65
Case age group at
diagnosis
≤40 60 (69%) 27 (31%) Referent Referent Referent Referent
41 to 50 600 (49.3%) 618 (50.7%) 0.44 0.27, 0.69 0.82 0.45, 1.48
51+ 1,383 (53.6%) 1,195 (46.4%) 0.52 0.33, 0.83 0.84 0.45, 1.57
Diagnosis year
Before 2000 194 (84%) 37 (16%) Referent Referent Referent Referent
2001 to 2004 406 (85.3%) 70 (14.7%) 1.11 0.72, 1.71 1.30 0.83, 2.05
2005 to 2009 1,443 (45.4%) 1,733 (54.6%) 0.16 0.11, 0.23 1.27 0.80, 2.00
Ethnicitya
Hispanic 163 (31.2%) 360 (68.8%) 0.39 0.32, 0.47 0.62 0.50, 0.78
Non-Hispanic 1,656 (54%) 1,410 (46%) Referent Referent Referent Referent
Race
Nonwhite 329 (48.9%) 344 (51.1%) 0.84 0.71, 0.98 0.66 0.51, 0.84
White 1,714 (53.4%) 1,496 (46.6%) Referent Referent Referent Referent
Rural or urban status
Rural 425 (57.2%) 318 (42.8%) 1.26 1.07, 1.48 1.31 1.08, 1.58
Urban 1,618 (51.5%) 1,522 (48.5%) Referent Referent Referent Referent
Sex
Female 960 (55.6%) 767 (44.4%) 1.24 1.09, 1.41 1.25 1.07, 1.46
Male 1,083 (50.2%) 1,073 (49.8%) Referent Referent Referent Referent
Cancer stage
Local 869 (49%) 905 (51%) Referent Referent Referent Referent
Regional or distant 1,174 (55.7%) 935 (44.3%) 1.31 1.15, 1.48 1.05 0.91, 1.23
Registry source
California 827 (33.9%) 1,611 (66.1%) Referent Referent Referent Referent
Idaho 115 (83.9%) 22 (16.1%) 10.18 6.40, 16.19 8.28 5.11, 13.41
Colorado 213 (81.9%) 47 (18.1%) 8.83 6.37, 12.24 7.12 5.97, 18.98
New Mexico 51 (64.6%) 28 (35.4%) 3.55 2.22, 5.67 3.32 2.04, 5.41
Utah 837 (86.4%) 132 (13.6%) 12.35 10.09, 15.11 10.89 8.08, 14.66
a Due to small numbers (n ≤ 5), those with other family relationships to the cancer case (e.g., nephew, niece) were not included in the analysis.
b Due to limited data availability, rural/urban status for non-consenting cases could not always be determined. Thus, these individuals (n = 161) are missing from
the data.
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these individuals by study staff proved difficult; and the
effect extended into relative recruitment, as only 34 rela-
tives (7% of the total study population) of California cases
were recruited into the study. This is an important consid-
eration for future studies, as low initial contact costs may
not translate into low total recruitment costs.
Nonwhite race and Hispanic ethnicity were associated
with nonparticipation among cancer cases in the Utah andIdaho registries at recruitment Stage 2. This finding is con-
gruent with previous studies that have shown nonwhite
race and Hispanic ethnicity to be significant factors of
nonparticipation in screening intervention trials [23-25].
Lai et al. [26] found that interventions that utilize culturally
targeted strategies to recruit underrepresented groups had
more effective recruitment outcomes. Our study utilized
cancer registries as our recruitment source; more research
is needed to determine what, if any, targeted recruitment
Simmons et al. Trials 2013, 14:116 Page 10 of 12
http://www.trialsjournal.com/content/14/1/116strategies aimed at increasing racial and ethnic participation
would be effective through a cancer registry [27].
In Stage 2, rural cancer cases were more likely to re-
turn the form than their urban counterparts. This find-
ing is novel and further investigations are needed to
determine what mechanisms influence participation at
this level. Our study was designed to reach individuals in
geographically underserved settings for remote inter-
vention, which might have appealed to rural cancer
cases, making them more likely to participate. This in-
crease in participation by rural cases was not mirrored
by an increase in rural relative enrollment, which sug-
gests that recruitment of cases and at-risk relatives
might be motivated by different factors. Additional re-
search examining the differences in motivation to par-
ticipate between cancer cases and their relatives would
be valuable, if indeed different recruitment strategies
would be more effective in recruiting each population.
More than half of our study participants (52.2%) had
another family member enrolled in the study. Family
participation was found to be a significant predictor of
relative enrollment with individuals more likely to enroll
when other family members also participated. This sup-
ports the findings of Glanz et al. [13], who reported that
63% of participants in their intervention study examin-
ing CRC-risk counseling had at least one other first-
degree relative enrolled. Familial support has been found
to be an important component of adherence to colorec-
tal screening recommendations; our outcomes build on
the idea that such support may also influence relative
decision to enroll in CRC screening trials [28].
Our intervention targeted both those who had never
undergone colonoscopy and those who were overdue for
colonoscopy. Individuals were more likely to enroll in
our study if they had already undergone colonoscopy
before. Known barriers in obtaining a colonoscopy in-
clude fear about the procedure and concerns about the
preparation; it is possible that individuals who had been
through the process had fewer psychological barriers
than those who had never experienced the procedure,
and were thus more likely to enroll [29]. Future studies
with interest in enrolling only participants who have
never undergone screening may need to adjust target re-
cruitment goals to reflect these barriers.
One study limitation was our inability to analyze inter-
registry predictors of recruitment, owing to differences
in registry protocols and in the data provided. Although
intra-registry comparisons provide insight into the fac-
tors potentially affecting recruitment within a registry, it
is impossible to determine whether true similarities or
differences exist between all-registry outcomes. This
inhibited our ability to determine the true extent to
which registry protocols, contact intensity, and diagnosis
years influenced the recruitment process.Another limitation of our study was the restricted
amount of information we were able to obtain on non-
consenting cancer cases and on relatives whom study staff
were not able to contact directly. Cancer surveillance data
collected by registries do not include information con-
cerning education level, income, socioeconomic status, or
other potentially influencing factors. Consequently, we
could not assess the effect these variables might have on
recruitment outcomes. Furthermore, privacy concerns for
nonconsenting registry cases restricted the types of data
available for analysis. Data limitations were also present in
at-risk relatives, as information about eligible relatives was
provided by cancer cases; this limited our ability to obtain
certain demographic data on nonconsenting relatives.
Although we have provided information about direct
costs related to recruitment, a complete cost analysis
that accounted for indirect costs, such as institutional
fees, administrative salaries, fringe benefits and other
items was not feasible within the scope of this paper.
However, as our limited data indicate, costs of identifica-
tion, contact, and recruitment for behavioral interventions
depend on many factors. Further research could provide
an important perspective on potential ways to minimize re-
cruitment costs while maximizing outcomes in these popu-
lations. As indirect costs can vary dramatically by state and
institution, including direct cost information might repre-
sent more comparable data for design of future trials.
Conclusions
Our research provides evidence that recruitment of families
through cancer registries remains a feasible but time and
labor-intensive process, which involves sifting through a sig-
nificant number of ineligible or uninterested individuals in
order to enroll each study participant. Registry source was
an important predictor of participation of both cancer cases
and their at-risk relatives. Investigators who are interested in
conducting other studies using population-based registries
might wish to factor the recruitment protocols of an identi-
fied cancer registry into time and budgetary considerations,
as differing protocols might require more effort and cost in
subsequent recruitment stages. Race, ethnicity, sex, and rural
residence were predictive of cancer-case participation; while
family participation and Utah residency affected relative par-
ticipation. Future studies that aim to increase population
diversity might consider culturally-specific recruitment strat-
egies, or might need to specify oversampling in cancer regis-
tries with highly diverse populations. Theoretically guided
and culturally targeted recruitment strategies that enhance
family support in familial cancer screening interventions
might find greater success in enrollment if family units, ra-
ther than individuals, are engaged. These findings provide a
unique contribution to the literature and emphasize the need
for effective recruitment strategies to familial cancer preven-
tion randomized trials that address potential determinants of
Simmons et al. Trials 2013, 14:116 Page 11 of 12
http://www.trialsjournal.com/content/14/1/116participation in screening interventions by cancer cases and
enrollment of their at-risk family members.
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